CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shield Therapeutics PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shield Therapeutics PLC
3rd Fl
Baltic Business Quarters, Abbott's Hill
Phone: +44 1915118500p:+44 1915118500 GATESHEAD, NE8 3D  United Kingdom Ticker: STXSTX
Business Summary
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
8049 Offices and clinics of health practitioners, not elsewhere classified
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Hans P.Hasler 67 6/18/2020 7/1/2018
Chief Executive Officer, Executive Director Gregory P.Madison 55 6/18/2021 6/1/2021
Chief Financial Officer SantoshShanbhag 46 1/16/2024 1/16/2024
8 additional Officers and Directors records available in full report.

Business Names
Business Name
1JS
SHIEF
STX

General Information
Number of Employees: 28 (As of 12/31/2022)
Outstanding Shares: 782,056,367 (As of 10/4/2023)
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024